- Home
- AXNX
AXNX
Axonics Inc.
as 07-26-2024 4:00pm EST
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $70.71 | AVG Volume (30 days): | 339.9K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $48.30 - $69.68 | Next Earning Date: | 08-06-2024 |
| Revenue: | $387,138,000 | Revenue Growth: | 30.82% |
| Revenue Growth (this year): | 24.48% | Revenue Growth (next year): | 19.96% |
Stock Insider Trading Activity of Axonics Inc. (AXNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Noblett Karen | AXNX | Chief Medical Officer | Jan 31 '24 | Sell | $67.74 | 11,288 | $764,602.84 | 34,428 | SEC Form 4 |
| Ford Alfred J Jr | AXNX | Chief Commercial Officer | Jan 31 '24 | Sell | $67.74 | 16,615 | $1,125,431.98 | 43,450 | SEC Form 4 |
| Keese Kari Leigh | AXNX | Chief Financial Officer | Jan 31 '24 | Sell | $67.74 | 3,489 | $236,330.56 | 43,323 | SEC Form 4 |
| Woock John | AXNX | EVP, Chief Mktg/Strtgy Officer | Jan 31 '24 | Sell | $67.74 | 15,899 | $1,076,933.07 | 77,403 | SEC Form 4 |
| COHEN RAYMOND W | AXNX | Chief Executive Officer | Jan 31 '24 | Sell | $67.74 | 35,161 | $2,381,661.98 | 188,835 | SEC Form 4 |
| Noblett Karen | AXNX | Chief Medical Officer | Jan 8 '24 | Sell | $69.00 | 15,999 | $1,103,961.40 | 18,216 | SEC Form 4 |
| Noblett Karen | AXNX | Chief Medical Officer | Dec 26 '23 | Sell | $63.00 | 949 | $59,787.00 | 41,266 | SEC Form 4 |
| Noblett Karen | AXNX | Chief Medical Officer | Dec 26 '23 | Sell | $63.28 | 7,051 | $446,176.70 | 34,215 | SEC Form 4 |
Latest Axonics Inc. News
AXNX Breaking Stock News: Dive into AXNX Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Business Wire
2 months ago
Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
GlobeNewswire
2 months ago
Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
Compare AXNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXNX Axonics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.